Through Septodont–Egalet agreement, Septodont will have exclusive marketing rights to promote Sprix (ketorolac tromethamine) nasal spray within the United States.
Septodont signed an agreement with Egalet Corporation, a specialty pharmaceutical company, for exclusive marketing rights to promote Sprix (ketorolac tromethamine) nasal spray to the dental market in the United States.
Sprix nasal spray is indicated as an alternative to opioid or steroid therapy. It is a short-term treatment (five days, maximum) for adults to manage moderate to moderately severe pain that would require analgesia at the opioid level.
For the full prescribing information on Sprix nasal spray, including the boxed warning, visit sprix.com.
MORE NEWS FROM SEPTODONT:
Septodont acquires injectable dental anesthetic manufacturing plant from Dentsply International
Septodont initiative benefits kids served by America's ToothFairy
